otavirus is the most common global cause of severe early childhood gastroenteritis and has a significant clinical impact. 1 In the pre-vaccine era, it was responsible for about 10 000 hospitalisations, 22 000 emergency department presentations and 115 000 general practice consultations annually in Australian children less than 5 years of age. 2 To reduce this substantial disease burden, two rotavirus vaccines have been licensed for use in Australian infants: RotaTeq (Merck, Whitehouse Station, NJ, USA), a live multivalent bovine-human reassortant vaccine; 3 and Rotarix (GlaxoSmithKline, Rixensart, Belgium), a single-strain liveattenuated human vaccine. 4 Australian infants have been eligible for rotavirus vaccination via the National Immunisation Program since July 2007. 5 Queensland children born on or after 1 May 2007 are eligible for three publicly funded doses of RotaTeq. Both vaccines were available on the private market from 2006, but, as with other recommended but non-funded vaccines, 6 uptake is likely to have been modest.
The aim of our study was to examine the effect of introducing the publicly funded infant rotavirus vaccination program on disease notifications and on laboratory testing and results.
METHODS
To assess the impact of the first 18 months of the infant vaccination program in Queensland, we used two sources: routinely collected rotavirus notifications made to Queensland Health (2006) (2007) (2008) 
Statistical analysis
Data were analysed using Stata software, version 9 (StataCorp, College Station, Tex, USA).
Ethics approval
Our project was approved as low-risk research 7 by Queensland' s Children's Health Services District Ethics Committee. 
RESULTS

Notifications
Request slip audit
The audit of 2008 request slips showed that for patients in the oldest age group (у 65 years) there was less likely to be a specific request for rotavirus testing or adenovirus testing (which would also result in a rotavirus test as part of the dual test kit) than for those aged less than 2 years (63% [38/60] v 82% [49/60], respectively; P = 0.025). Further, comparing the oldest age group with the youngest, a larger proportion of rotavirus tests performed appeared to be done in response to a request for non-specific viral testing in the absence of either a specific rotavirus or adenovirus request (35% [21/ 60] v 13% [8/60], respectively; P = 0.006). Concordant findings have been seen elsewhere: rotavirus activity was delayed by up to 4 months and diminished in size by more than 50% in the United States after the introduction of the RotaTeq vaccine, 8 and there was evidence of vaccine effectiveness during a recent outbreak in the Northern Territory, where the Rotarix vaccine is used. 9 Our Queensland data are an important addition to current findings, as they are among the first to show changes in rotavirus epidemiology in non-vaccinated age groups, 10 providing good evidence for an equivalent indirect vaccine effect in older age groups. These local outcomes were achieved within 18 months of the program's commencement. Of the first two eligible birth cohorts in which coverage was measured, 75% of infants born in May-July 2007 and 80% of those born in August-September 2007 had received a complete threedose vaccine course on assessment at 12 months of age (Mr Brynley Hull, Epidemiologist, National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, personal communication). Improved benefits are anticipated as more birth cohorts are vaccinated and more courses completed.
Our only divergent finding was the increase in the number of tests performed for rotavirus in older age groups. The request slip audit showed that in the oldest age group there was less likely to be a specific request for rotavirus or adenovirus testing, and that the proportion of rotavirus tests done in response to a request for nonspecific viral testing was higher. There has recently been an increased awareness of viral gastroenteritis outbreaks in hospitals, nursing homes and residential aged-care facilities. 11, 12 It may be that, in some circumstances, rotavirus testing is being done routinely on gastroenteritis specimens from older people, even though the overall number and proportion of specimens found positive is likely to be low.
Our data come from two passive, routinely collected sources. Both are likely to be reasonably representative of all regions in Queensland, and the data from 33 Queensland Health laboratories are likely to include nearly all testing done in rural and remote locations, which are not as well served by private pathology companies. It is worth keeping in mind that our results are produced from observational studies relating trends in rotavirus outcome data before and after vaccine introduction: this is a less robust study design than other observational studies for assessing a causal relationship. The documented changes may represent secular trends -however, the results would represent unusual, persisting and extreme temporal variations. Further, the reductions seen coincide closely with vaccine introduction, and are in keeping with both US post-licensure data 8 and vaccine efficacy studies showing a 98%-100% reduction in severe rotavirus gastroenteritis and a 73%-74% reduction in any rotavirus gastroenteritis. 3, 13 To support the role of vaccination in these locally improving trends, better quality observational studies are required, including efforts to estimate vaccine effectiveness using routinely collected data 14 and during identified outbreaks. 9 Australia, being in the unique position of having widespread and region-specific use of both currently licensed rotavirus vaccines, could further add to global research by routinely monitoring the field effectiveness of each vaccine, as well as regional differences in circulating genotypes, through the National Rotavirus Reference Centre. 15 Our results, in conjunction with efficacy trial data and findings from the US, provide solid support for prompt direct and indirect effects following rotavirus vaccine use in Queensland. This should encourage parents and vaccination providers to ensure that all Australian children receive the recommended rotavirus vaccine course within the required timeframe. 
